NorthEast Monitoring Inc. released LX Sleep, a software product that reportedly detects OSA from data collected during a simplified, overnight, at-home, patient hookup to its OxyHolter product.

Northeast Monitoring has introduced the DR200/HE, a combination 14-day Holter plus 30-day Event recorder integrated into a single unit that is designed for deployment to patients in either 'Holter' or 'Event' mode.

AtriCure’s Coolrail linear ablation pen for the ablation of cardiac tissue can be used for patients with persistent and long-standing persistent atrial fibrillation, according to the company, which provides minimally invasive products.

Bacchus Vascular Inc. has developed a catheter-based device, the Trellis-8 infusion catheter, which disperses thrombolytic solution directly into the clot of patients with deep vein thrombosis (DVT), is said to be safe and effective, according to data presented at the 33rd annual meeting of the Society of Interventional Radiology, held March 16, 2008.

McKesson has released a new Horizon Cardiology product for the cath lab, the Holding Area Charting, designed to simplify and expedite information flow in the cath lab, increase data accuracy by minimizing duplication and strengthen the facility’s commitment to patient safety.

The Society for Cardiovascular Angiography and Interventions (SCAI) has partnered with the American College of Cardiology (ACC) to co-locate its 33rd annual meeting with the ACC.08 57th Annual Scientific Session to form the new SCAI-ACCi2 meeting.

March 18, 2008 - Abiomed Inc. received conditional approval from the FDA to begin its Impella 2.5 Circulatory Support System study in the U.S. under an investigational device exemption (IDE) for hemodynamically unstable patients undergoing a percutaneous coronary intervention (PCI) procedure due to acute myocardial infarction (AMI).

March 13, 2008 – Abbott’s fully bioabsorbable drug-eluting stent for the treatment of coronary artery disease demonstrated no stent thrombosis, no clinically driven target lesion revascularizations and a 3.3 percent rate of major adverse cardiac events (MACE) in 30 patients out to one year, according to data from the ABSORB clinical trial published in The Lancet on March 13, 2008.

March 13, 2008 - Signalife Inc. received the Frost and Sullivan 'Technology Innovation Award for North American Patient Monitoring' for its artifact reducing technology, marking the second time the company has received this award.

Frost and Sullivan gave Signalife the award for its Fidelity heart monitoring systems, which Frost and Sullivan said provides signal clarity in the wireless cardiac monitoring arena.

March 11, 2008 – The FDA cleared an investigational device exemption (IDE) application from Life Recovery Systems to use the ThermoSuit noninvasive cooling system to investigate rapid hypothermia treatment in combination with primary angioplasty to treat heart attacks.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now